Skip to content
Sign in
SWC 2026 FinalistGrand Final: Lunch Block

Yeast Bay Bio

Davis biotech using baker’s yeast to deliver RNAi that kills insect pests, starting with cockroaches, without hazardous chemicals.

Davis, CA, United States, North AmericaAgri & FoodTech, Yeast-based RNAi biopesticidesUSA – Sacramento Regional 2026 (listed among the 10 finalists; win not confirmed by any source)
Stage
SeedNo documented AI
Product
R&DNone known
Funding raised
Undisclosedamount not disclosed
Founded
20251 years ago
Founders
2Dr, Lisa
Global score
3.5Grade DRank 111 of 151

Overview

Pre-commercial biotech startup founded in 2025 in Davis (California) developing a biopesticide platform: a yeast delivers RNA interference sequences targeting insect pests, without hazardous chemicals; first target: cockroaches (YBB-01 RNAi product).

Traction

None known

RNAi biopesticide platform in development (initial target: cockroaches); no registered product or customer announced.

Market

Biopesticides (including RNAi)

Chemical insecticides face resistance, regulatory bans and consumer concern, pushing pest control and agriculture toward biological alternatives. RNA interference offers species-specific action, and yeast is a cheap, safe delivery vehicle. Initial buyers for a cockroach product are pest-control operators and consumer products; agricultural crop pests would follow with longer registration. Regulatory registration (EPA) is the gating factor.

Addressable market

2025
$8.9B
2030
$17.7B
+14.6% a year

Biopesticides: $8.94bn in 2025 to $17.68bn in 2030 (CAGR 14.6%, MarketsandMarkets); RNAi is a small fraction.

Customers

Pest-control operators and consumer pest products first; later growers

Who signs the cheque

Pest-control companies, consumer brands, agricultural input distributors

Geographies

  • United States

Drivers

  • Insecticide resistance and bans
  • Demand for safer biologicals
  • Species-specific RNAi science

Headwinds

  • Long registration process
  • No product yet
  • Manufacturing scale and stability

Global biopesticide market from $8.94bn in 2025 to $17.68bn in 2030 (CAGR 14.6%) according to MarketsandMarkets; the RNAi sub-segment represents only a small fraction.

Scalability 4/10. Biopesticide requiring registration country by country (EPA, EU) with multi-year timelines.

Market source: marketsandmarkets.com

Technology

Category

Agricultural / urban biotech (RNAi biopesticide)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

R&D

How it works

Saccharomyces cerevisiae is used as the RNAi vector, delivering sequences that silence essential pest genes. The platform is modular: changing the RNA sequence targets other species.

Moat

Moderate: platform know-how and sequence IP; entomologist founder ex-Novonesis.

Differentiation

Low-cost yeast delivery and species specificity versus broad chemical insecticides.

Integration points

  • Bait and formulation partners
  • Agricultural input distribution
  • Field-trial networks

Depends on

  • EPA registration
  • Field efficacy data
  • Fermentation scale-up

Use of AI

No use of AI mentioned

Product in detail

Saccharomyces cerevisiae used as an RNAi vector; modular platform extended to other pest species by changing the RNA sequence.

Business

Model
Product sales or licensing of RNAi products (not yet defined).
Revenue logic
Not disclosed.
Go-to-market
First urban pest (cockroach) product, then crop pests.

Next milestones

  1. Efficacy data for YBB-01
  2. EPA registration filing
  3. Seed 2 round

Key risks

  • Regulatory timeline
  • No product
  • Funding

Opportunities

3 found in the network

Concrete moves for Yeast Bay Bio inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Distribution 1
  • Investors 2

Distribution1

A channel or customer base to reach together

Use Chonex’s grower trial network for the first crop-pest targets

Chonex sells biological inputs with 550+ field trials and grower relationships in blueberries, citrus and grapes; when Yeast Bay moves from cockroaches to crop pests, it needs trial sites and a channel. Chonex gains a complementary biopesticide for its portfolio.

20%confidence

Evidence from the records

  • “modular platform extended to other pest species by changing the RNA sequence”
  • “550+ field trials and grower testimonials (blueberries, citrus, grapes)”
If it works
Co-run field trials and a future distribution agreement.
First step
Hold a call with Chonex to identify priority pests in its grower base.

Investors2

A fund whose thesis fits

Apply to SOSV/IndieBio for platform funding

SOSV backs deep tech for human and planetary health and ran IndieBio for network member ZymoChem; synthetic-biology biopesticides are squarely in scope.

25%confidence

Evidence from the records

  • “Backs deep tech companies working on human and planetary health from pre-seed through follow-on rounds.”
  • “IndieBio (SOSV)”
If it works
Capital plus lab and regulatory support.
First step
Submit an application to the next IndieBio cohort citing ZymoChem as reference.

Pitch Cavallo for the Seed 2 round

Cavallo invests in Agri & FoodTech from seed onward and backed network member ZymoChem; a biopesticide platform fits its agricultural thesis.

20%confidence

Evidence from the records

  • “GS Futures, KdT Ventures, Cavallo Ventures (existing investors before the Series A)”
  • “seed 2”
If it works
A strategic co-investor in Seed 2.
First step
Ask ZymoChem for an intro to Cavallo Ventures.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Physician-founded Austin VC ($250M+ AUM) backing science-driven therapeutics, digital health, industrial biotech and climate companies.

US seed yeast-based RNAi biopesticides — industrial biotech platform, KdT's ZymoChem playbook.

60%confidence

Evidence from the records

  • “industrial biotech”
  • “Yeast-based RNAi biopesticides”
  • “RNAi biopesticide platform in development (initial target: cockroaches)”
Intro path
Founder-to-founder intro via ZymoChem (network portfolio company of KdT Ventures).
First step
Ask ZymoChem's founders for an intro.

Self-described most active pre-seed deep-tech investor, backing human and planetary health from pre-seed through follow-on rounds.

Yeast-delivered RNAi biopesticides, founded 2025: synthetic biology for planetary health at the earliest stage, SOSV's core pattern.

55%confidence

Evidence from the records

  • “Yeast-based RNAi biopesticides”
  • “RNAi biopesticide platform in development”
Intro path
ZymoChem founders (SOSV portfolio).
First step
Apply to SOSV's bio accelerator.

US federal agency funding startups through non-dilutive SBIR/STTR grants (America's Seed Fund); backed G-Space and BioSapien.

Yeast-delivered RNAi biopesticides from Davis, founded 2025: novel biotech with feasibility to prove.

50%confidence

Evidence from the records

  • “Yeast-based RNAi biopesticides”
  • “Pre-commercial biotech startup founded in 2025”

US accelerator network investing $100,000 per startup through 12-week programmes across climate, health, agri, fintech and deep tech.

US seed agri-biotech (RNAi biopesticides) — adjacent to Chonex's agricultural inputs and inside gener8tor's Agri & FoodTech and Biotech lists. A $100K accelerator cheque is proportionate at seed.

55%confidence

Evidence from the records

  • “"Agri & FoodTech"”
  • “Yeast-based RNAi biopesticides”
  • “RNAi biopesticide platform in development (initial target: cockroaches)”
Intro path
Founder-to-founder intro via Chonex (network portfolio company of gener8tor).
First step
Shortlist the agri/bio gener8tor programme and request a Chonex founder reference.

San Francisco early-stage investor pairing technology with science: drug discovery, climate, neurotech and lab automation (ZymoChem).

US yeast-based RNAi biopesticides: synbio for agriculture, adjacent to ZymoChem. R&D stage at seed.

45%confidence

Evidence from the records

  • “Yeast-based RNAi biopesticides”
  • “United States”
Intro path
ZymoChem (synbio peer)
First step
Ask ZymoChem for an intro.

St. Louis non-profit awarding equity-free US$75,000 grants to startups that relocate to St. Louis.

US yeast-based RNAi biopesticides at seed (R&D): an ag-bio company that would gain from St. Louis's plant-science ecosystem. Relocation is the key condition.

40%confidence

Evidence from the records

  • “Yeast-based RNAi biopesticides”
  • “United States”
Intro path
Amass Biosystems (Arch Grants 2026, network peer)
First step
Assess relocation feasibility and apply in the next cycle.

Wilbur-Ellis's stage-agnostic CVC backing agribusiness software, soil health, food ingredients and animal nutrition, with distribution through Wilbur-Ellis.

Yeast-based RNAi biopesticides: crop protection for a distributor portfolio, but R&D-stage with cockroaches as the first target.

40%confidence

Evidence from the records

  • “Yeast-based RNAi biopesticides”
  • “initial target: cockroaches”
Intro path
ZymoChem (synbio peer)
First step
Show an ag-pest roadmap before pitching.

US family office with no public profile in our data; invested in Chonex's $5.78M seed (black soldier fly agri-inputs).

US yeast RNAi biopesticides at seed — agri inputs like Chonex.

35%confidence

Evidence from the records

  • “Chonex”
  • “Yeast-based RNAi biopesticides”
  • “RNAi biopesticide platform in development (initial target: cockroaches)”
Intro path
Founder-to-founder intro via Chonex (network portfolio company of Jemison Investment Company).
First step
Ask Chonex for an introduction.

US corporate venture investor with no profile in our data; backed synthetic-biology materials company ZymoChem at seed and Series A.

US seed yeast-based RNAi biopesticides — industrial biotech platform.

30%confidence

Evidence from the records

  • “seed”
  • “Yeast-based RNAi biopesticides”
  • “RNAi biopesticide platform in development (initial target: cockroaches)”
Intro path
Founder-to-founder intro via ZymoChem (network portfolio company of GS Futures).
First step
Qualify GS Futures' sector appetite via KdT Ventures.

US non-profit research institute; supported insect-based ag-input company Chonex through its Prosperity Fund and seed round.

US yeast-based RNAi biopesticides: crop-protection science adjacent to Chonex.

25%confidence

Evidence from the records

  • “Yeast-based RNAi biopesticides”
  • “Seed”
Intro path
Chonex founders.
First step
Ask Chonex about the Prosperity Fund criteria.

Investment analysis

3.5D

Grade D

Rank 111 of 151

Disruption7.0/10
Business model1.0/10
Market4.0/10
Risk(lower is better)9.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early.

Disruption

7/10

Yeast-delivered RNAi biopesticides: a new approach.

Business model

1/10

R&D, no registered product.

Market

4/10

TAM biopesticides (including RNAi) ~$8.94bn (base 5), low scalability 4/10 (−1), no proven international expansion (0) → 4/10.

Risk

9/10

Lower is better

Very high risk: long registration process, company founded in 2025.

Strengths

  • Entomologist founder
  • RNAi platform

Risks

  • Long registration process
  • No product

Funding

Undisclosed, amount not disclosed
  1. 1er juil. 2026 (PitchBook)

    seed (amount not disclosed)not disclosed

    California Innovation Fund

  2. à venir (PitchBook)

    seed 2not disclosed

    —

Amount used in the study. Seed (California Innovation Fund) with no published amount.

Note. amount not public

Business confirmed by the site (yeast-delivered RNAi biopesticides, cockroach target) → sector/description/technology corrected; seed dated 1 July 2026 (PitchBook); participation in the SWC Sacramento 2026 regional.

Team

  • Dr Nazzy Pakpour

    Co-founder & CEO

    Entomologist, BS UC Davis, PhD UPenn, former assistant professor at CSU East Bay and Senior Scientist at Novonesis.

  • Lisa Jann

    Co-founder & COO

    MBA UCLA Anderson, BA UC Berkeley; 20+ years leading a major West Coast cultural organization.

Sources

Regional final
USA – Sacramento Regional 2026 (listed among the 10 finalists; win not confirmed by any source)
Identification confidence
medium
  1. 1pitchbook.com/profiles/company/1326543-67
  2. 2yeastbaybio.com/
  3. 3luma.com/31cagcl7

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet